Claro Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $829K | Buy |
21,868
+256
| +1% | +$11.8K | 0.08% | 211 |
|
|
2026
Q2 | $1.04M | Sell |
21,612
-1,589
| -7% | -$68.3K | 0.11% | 159 |
|
|
2026
Q1 | $853K | Buy |
23,201
+2,282
| +11% | +$108K | 0.1% | 167 |
|
|
2025
Q4 | $1.06M | Sell |
20,919
-100
| -0.5% | -$5.11K | 0.15% | 123 |
|
|
2025
Q3 | $1.17M | Sell |
21,019
-204
| -1% | -$11.9K | 0.17% | 109 |
|
|
2025
Q2 | $1.46M | Sell |
21,223
-162
| -0.8% | -$11K | 0.24% | 87 |
|
|
2025
Q1 | $1.48M | Buy |
21,385
+113
| +0.5% | +$9.33K | 0.2% | 95 |
|
|
2024
Q4 | $1.83M | Sell |
21,272
-4,816
| -18% | -$521K | 0.25% | 78 |
|
|
2024
Q3 | $3.11M | Buy |
26,088
+2,509
| +11% | +$335K | 0.4% | 49 |
|
|
2024
Q2 | $3.37M | Buy |
23,579
+341
| +1% | +$45.2K | 0.53% | 37 |
|
|
2024
Q1 | $2.98M | Buy |
23,238
+743
| +3% | +$88.4K | 0.52% | 39 |
|
|
2023
Q4 | $2.33M | Buy |
22,495
+17
| +0.1% | +$1.68K | 0.5% | 40 |
|
|
2023
Q3 | $2.04M | Sell |
22,478
-314
| -1% | -$27.7K | 0.51% | 39 |
|
|
2023
Q2 | $1.84M | Buy |
22,792
+180
| +0.8% | +$14.7K | 0.46% | 43 |
|
|
2023
Q1 | $1.8M | Sell |
22,612
-38
| -0.2% | -$2.7K | 0.53% | 40 |
|
|
2022
Q4 | $1.53M | Buy |
22,650
+780
| +4% | +$45.7K | 0.5% | 47 |
|
|
2022
Q3 | $1.22M | Hold |
21,870
| – | – | 0.48% | 44 |
|
|
2022
Q2 | $1.22M | Buy |
21,870
+996
| +5% | +$55.3K | 0.48% | 44 |
|
|
2022
Q1 | $1.17M | Hold |
20,874
| – | – | 0.42% | 54 |
|
|
2021
Q4 | $1.17M | Buy |
20,874
+490
| +2% | +$26.5K | 0.42% | 54 |
|
|
2021
Q3 | $979K | Buy |
20,384
+2,416
| +13% | +$117K | 0.41% | 57 |
|
|
2021
Q2 | $753K | Buy |
17,968
+156
| +0.9% | +$6.05K | 0.34% | 77 |
|
|
2021
Q1 | $600K | Sell |
17,812
-2,792
| -14% | -$99.4K | 0.3% | 90 |
|
|
2020
Q4 | $720K | Buy |
20,604
+148
| +0.7% | +$5.12K | 0.38% | 75 |
|
|
2020
Q3 | $710K | Sell |
20,456
-246
| -1% | -$8.2K | 0.45% | 62 |
|
|
2020
Q2 | $678K | Buy |
20,702
+360
| +2% | +$11.5K | 0.47% | 59 |
|
|
2020
Q1 | $612K | Buy |
20,342
+584
| +3% | +$17.4K | 0.57% | 48 |
|
|
2019
Q4 | $572K | Buy |
19,758
+2,110
| +12% | +$58.4K | 0.44% | 66 |
|
|
2019
Q3 | $456K | Buy |
17,648
+48
| +0.3% | +$1.21K | 0.4% | 73 |
|
|
2019
Q2 | $449K | Buy |
17,600
+316
| +2% | +$7.81K | 0.41% | 70 |
|
|
2019
Q1 | $452K | Sell |
17,284
-288
| -2% | -$7.08K | 0.45% | 67 |
|
|
2018
Q4 | $414K | Buy |
+17,572
| New | +$390K | 0.33% | 71 |
|
Other funds holding NVO
Claro Advisors's NVO Position: Q3 2026 in Review
Claro Advisors increased its Novo Nordisk (NVO) stake by 1.2% in Q3 2026, buying an estimated $11.8K and bringing the position to 21,868 shares worth $829K. The position accounts for 0.08% of the portfolio, ranked #211.
Claro Advisors first reported a position in NVO in Q4 2018 and has held it in 32 quarters since. The position peaked at $3.37M in Q2 2024. 1,227 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Claro Advisors held 21,868 shares of Novo Nordisk worth $829K as of Q3 2026.
- Claro Advisors bought 256 Novo Nordisk shares in Q3 2026, an estimated $11.8K.
- Novo Nordisk made up 0.08% of Claro Advisors's portfolio in Q3 2026, its #211 holding.
- Claro Advisors first reported a position in Novo Nordisk in Q4 2018 and has held it in 32 quarters since.
- Claro Advisors's Novo Nordisk position peaked at $3.37M in Q2 2024.
- 1,227 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Claro Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.